May 16 - As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its ...

On Wall Street, Charter Communications rose 1.8% after it said it agreed to merge with Cox Communications in a deal that ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new ...

Stocks closed solidly higher on Friday, pushing major indexes to big weekly gains for the third time in the last four weeks.

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Lars Rebien Sorensen becomes CEO after serving as the head of Novo's healthcare business. The company's enzymes business was ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...